Mon Sep 23 22:45:12 UTC 2024: ## Genmab A/S Stock Plunges to New 52-Week Low

**COPENHAGEN, DENMARK – September 23, 2024** – Genmab A/S (OTCMKTS:GNMSF), the Danish biotechnology company specializing in antibody therapeutics for cancer and other diseases, experienced a significant decline in its stock price on Monday, reaching a new 52-week low.

The stock traded as low as $236.45, closing the day at $237.52, down from the previous day’s close of $264.35. This drop represents a substantial decline of over 10%.

The company’s market cap currently stands at $15.53 billion, with a P/E ratio of 19.66 and a beta of 1.07. Genmab’s recent earnings report, released on August 8th, showed strong performance with $3.13 EPS for the quarter and $779.50 million in revenue.

However, despite the positive earnings, the stock’s significant decline indicates a potential shift in investor sentiment. Market analysts are speculating that the drop may be due to several factors, including broader market concerns, competition within the biotechnology sector, or potential changes in the company’s outlook.

Genmab’s key products include DARZALEX, a treatment for multiple myeloma, teprotumumab for thyroid eye disease, and Amivantamab for advanced gastric or esophageal cancer and NSCLC. The company’s focus on innovative cancer therapies continues to be a key driver of its business.

Investors are closely watching the situation to see if this decline is a temporary blip or signals a more significant trend for Genmab A/S.

Read More